Safety of carotid endarterectomy while on clopidogrel (Plavix): Clinical article

Scott D. Wait, Adib A. Abla, Brendan D. Killory, Robert M. Starke, Robert F. Spetzler, Peter Nakaji

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Object. Many patients undergoing carotid endarterectomy (CEA) regularly take clopidogrel, a permanent platelet inhibitor. The authors sought to determine whether taking clopidogrel in the period before CEA leads to more bleeding or other complications. Methods. The authors performed a retrospective, institutional review board - approved review of 182 consecutive patients who underwent CEA. Clinical, radiographic, and surgical data were gleaned from hospital and clinic records. Analysis was based on the presence or absence of clopidogrel in patients undergoing CEA and was performed twice by considering clopidogrel use within 8 days and within 5 days of surgery to define the groups. Results. Taking clopidogrel within 8 days before surgery resulted in no statistical increase in any measure of morbidity or death. Taking clopidogrel within 5 days was associated with a small but significant increase in operative blood loss and conservatively managed postoperative neck swelling. No measure of permanent morbidity or death was increased in either clopidogrel group. Conclusions. Findings in this study support the safety of preoperative clopidogrel in patients undergoing CEA.

Original languageEnglish (US)
Pages (from-to)908-912
Number of pages5
JournalJournal of neurosurgery
Volume113
Issue number4
DOIs
StatePublished - Oct 2010
Externally publishedYes

Keywords

  • Antiplatelet agent
  • Carotid endarterectomy
  • Clopidogrel

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Safety of carotid endarterectomy while on clopidogrel (Plavix): Clinical article'. Together they form a unique fingerprint.

Cite this